Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the prolonged addition of soluble fibers to usual drug therapy

被引:0
|
作者
Watanabe, Hideo [1 ]
Inoue, Takahisa [2 ]
Miyamoto, Licht [3 ]
Ono, Yoshito [1 ]
Matsumoto, Kinya [1 ]
Takeda, Masanori [1 ]
Tsuchiya, Koichiro [2 ]
机构
[1] Watanabe Hosp, Matsuyama, Ehime, Japan
[2] Tokushima Univ, Grad Sch, Dept Med Pharmacol, 1-78-1 Sho Machi, Tokushima 7708505, Japan
[3] Kanagawa Inst Technol, Dept Nutr & Life Sci, Lab Pharmacol & Food Sci, Atsugi, Kanagawa, Japan
来源
JOURNAL OF MEDICAL INVESTIGATION | 2024年 / 71卷 / 1-2期
关键词
Partially hydrolyzed guar gum (PHGG); irritable bowel syndrome (IBS); Crohn's disease (CD); ulcerative colitis (UC); short-chain fatty acid-producing bacteria; HYDROLYZED GUAR GUM; C-REACTIVE PROTEIN; FECAL CALPROTECTIN; ULCERATIVE-COLITIS; CROHNS-DISEASE; ACTIVITY INDEX; LACTOFERRIN; NUTRITION; DIARRHEA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives : Partially hydrolyzed guar gum (PHGG) is a soluble dietary fiber ; in addition to improving bowel movements, it maintains intestinal health by producing short-chain fatty acids. However, majority of clinical studies on PHGG have been concluded within a month and excluded usual drug therapy. Hence, this study aimed to determine the effects of long-term consumption of PHGG, in combination with drug therapy, on gut bacteria ratios, laboratory values for inflammatory response, and fecal characteristics. Methods and Results : The study was performed in patients with irritable bowel syndrome (IBS), Crohn's disease (CD), and ulcerative colitis (UC), by the administration of PHGG for six months while they continued their usual treatment. PHGG treatment caused significant changes in patients with IBS, including an increase in the abundance of short-chain fatty acid-producing bacteria, a significant decrease in Bacteroides abundance, and normalization of the Bristol scale of stool. In patients with UC, non-significant normalization of soft stools and decrease in fecal calprotectin were observed. Adverse events were not observed in any of the groups. Conclusion : Thus, it would be beneficial to include PHGG in the usual drug therapies of patients with IBS. J. Med. Invest. 71 : 121-128, February, 2024
引用
收藏
页码:121 / 128
页数:8
相关论文
共 37 条
  • [1] Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome
    Vila, Arnau Vich
    Imhann, Floris
    Collij, Valerie
    Jankipersadsing, Soesma A.
    Gurry, Thomas
    Mujagic, Zlatan
    Kurilshikov, Alexander
    Bonder, Marc Jan
    Jiang, Xiaofang
    Tigchelaar, Ettje F.
    Dekens, Jackie
    Peters, Vera
    Voskuil, Michiel D.
    Visschedijk, Marijn C.
    van Dullemen, Hendrik M.
    Keszthelyi, Daniel
    Swertz, Morris A.
    Franke, Lude
    Alberts, Rudi
    Festen, Eleonora A. M.
    Dijkstra, Gerard
    Masclee, Ad A. M.
    Hofker, Marten H.
    Xavier, Ramnik J.
    Alm, Eric J.
    Fu, Jingyuan
    Section, Cisca Wijmenga
    Section, Daisy M. A. E. Jonkers
    Zhernakova, Alexandra
    Weersma, Rinse K.
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (472)
  • [2] Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
    Cui, Xiufang
    Wang, Haiyang
    Ye, Ziping
    Li, Yi
    Qiu, Xinyun
    Zhang, Hongjie
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [3] Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms
    Xiufang Cui
    Haiyang Wang
    Ziping Ye
    Yi Li
    Xinyun Qiu
    Hongjie Zhang
    BMC Gastroenterology, 21
  • [4] Experiences of healing therapy in patients with irritable bowel syndrome and inflammatory bowel disease
    Andrew Soundy
    Rhonda T Lee
    Tom Kingstone
    Sukhdev Singh
    Pankaj R Shah
    Lesley Roberts
    BMC Complementary and Alternative Medicine, 15
  • [5] Experiences of healing therapy in patients with irritable bowel syndrome and inflammatory bowel disease
    Soundy, Andrew
    Lee, Rhonda T.
    Kingstone, Tom
    Singh, Sukhdev
    Shah, Pankaj R.
    Roberts, Lesley
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 15
  • [6] Erratum to: Experiences of healing therapy in patients with irritable bowel syndrome and inflammatory bowel disease
    Andrew Soundy
    Rhonda T. Lee
    Tom Kingstone
    Sukhdev Singh
    Pankaj R. Shah
    Sandy Edwards
    Lesley Roberts
    BMC Complementary and Alternative Medicine, 15
  • [7] Microbiome Changes Post Bovine IGG in Irritable Bowel Syndrome and Inflammatory Bowel Disease Patients
    Hazan, Sabine
    Papousis, Andreas
    Sfera, Adonis
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S181 - S182
  • [8] CHANGES IN THE INTESTINAL MICROBIOTA IN PATIENTS WITH ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME COMBINED WITH UROLITHIASIS
    Kyrian, O. A.
    Derkach, I. A.
    Dorofeyev, A. E.
    Rudenko, M. M.
    WORLD OF MEDICINE AND BIOLOGY, 2021, 77 (03): : 77 - 81
  • [9] DIETARY ADVANCED GLYCATION ENDPRODUCTS AND INTESTINAL INFLAMMATION IN INFLAMMATORY BOWEL DISEASE AND IRRITABLE BOWEL SYNDROME PATIENTS
    de Graaf, Marlijne C.
    Scheijen, Jean
    Spooren, Corinne
    Mujagic, Z.
    Pierik, Marie J.
    Keszthelyi, Daniel
    Schalkwijk, Casper
    Jonkers, Daisy
    GASTROENTEROLOGY, 2022, 162 (07) : S461 - S462
  • [10] The Intestinal Microbiota of Irritable Bowel Syndrome Patients Attenuates DSS-Induced Colitis
    Gobert, Alain P.
    Sagrestani, Giulia
    Delmas, Eve
    Dapoigny, Michel
    Wilson, Keith T.
    Del'Homme, Christophe
    Bernalier-Donadille, Annick
    GASTROENTEROLOGY, 2016, 150 (04) : S3 - S3